Sector News

Rumours resurface over Shire NPS bid

December 18, 2014
Life sciences
The rumour mill is running wild with renewed reports of a possible marriage between Dublin, Ireland-based Shire and US group NPS Pharmaceuticals.
 
As first reported by Bloomberg, citing sources close to the situation, Shire is considering making an offer for NPS should its flagship hormone replacement therapy Natpara receive a green light from US regulators.
 
Natpara (recombinant human parathyroid hormone) was filed with the US Food and Drug Administration in October for the treatment of hypoparathyroidism, and a decision is expected towards the end of January.
 
Though neither party has yet commented on the move, shares in NPS had leapt 20% and Shire’s stock was up nearly 3% in mid-afternoon trading on the Nasdaq on Wednesday.
 
Interestingly, these are not the first whispers of such a deal; back in June various media reports were suggesting that Shire is planning to make an offer in the region of $4 billion for NPS, though these soon were quashed by the US group.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).